Table 1.
Baseline patient characteristics
| Characteristic | Category | Patients N=51 (%) | Characteristics | Category | Patients N=51 (%) |
|---|---|---|---|---|---|
| Treatment | 90Y Radioembolization | 33 (65) | Platelets | Mean | 163,000/μL |
| Chemoembolization | 18 (35) | Median | 132,000/μL | ||
| Range | 39000 – 666000/μL | ||||
| Age (years) | <65 | 23 (45) | PVT | Present | 7 (14) |
| ≥65 | 28 (55) | Absent | 44 (86) | ||
| Ethnic Group | Caucasian | 29 (56) | Lobar Distribution | Unilobar | 48 (94) |
| Asian | 7 (14) | Bilobar | 3 (6) | ||
| Hispanic | 5 (10) | Tumor Size | ≤5 cm | 29 (57) | |
| African-American | 10 (20) | 5.1-10 cm | 16 (31) | ||
| Gender | Male | 30 (59) | >10 cm | 6 (12) | |
| Female | 21 (41) | AFP (ng/mL) | 200-1000 | 21 (41) | |
| Etiology | Alcohol | 7 (14) | >1000 | 30 (59) | |
| Hepatitis C Virus (HCV) | 20 (39) | ECOG | 0 | 25 (49) | |
| HCV + Alcohol | 2 (4) | 1 | 24 (47) | ||
| Hepatitis B Virus | 4 (8) | 2 | 2 (4) | ||
| Nonalcoholic Steatohepatitis | 1 (2) | UNOS | T1 | 1 (2) | |
| Cryptogenic | 8 (15) | T2 | 25 (49) | ||
| Autoimmune Hepatitis | 1 (2) | T3 | 18 (35) | ||
| Primary Biliary Cirrhosis | 3 (6) | T4b | 7 (14) | ||
| Hemochromatosis | 2 (4) | BCLC | A | 23 (45) | |
| Unknown | 3 (6) | B | 10 (20) | ||
| Method of Diagnosis | Imaging | 33 (65) | C | 18 (35) | |
| Biopsy | 18 (35) | Child-Pugh | A | 29 (57) | |
| Portal Hypertension | Present | 37 (73) | B | 22 (43) | |
| Absent | 14 (27) | Previous Therapy | RFA | 2 (4) | |
| Ascites | Present | 5 (10) | Resection | 1 (2) | |
| Absent | 46 (90) | Systemic Agents | 0 (0) | ||
| Cirrhosis | Present | 48 (94) | None | 48 (94) | |
| Absent | 3 (6) |
Abbreviations: AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; PVT: Portal Vein Thrombosis; RFA: radiofrequency ablation; UNOS: United Network for Organ Sharing